Company Overview

Braxia Scientific Corp. (CSE: BRAX) is a Canadian healthcare and biotechnology company focused on developing and delivering treatments for depression, post-traumatic stress disorder (PTSD), anxiety disorders, and other mental health conditions. The company operates primarily in the mental health and psychedelic medicine sectors, combining clinical psychiatric services with research into ketamine-assisted therapies and related neurological treatments. Braxia’s activities have historically included patient treatment through specialized clinics as well as clinical research aimed at expanding evidence-based psychiatric care.

The company’s principal revenue drivers have included patient care services delivered through psychiatric and mental health clinics, along with research-related activities tied to psychedelic and ketamine-based treatment models. Braxia evolved from earlier healthcare operations centered on depression treatment and later expanded into psychedelic medicine and neuropsychiatric research during the broader growth of the sector in Canada and internationally. Its strategic positioning has focused on integrating clinical infrastructure with research capabilities, allowing the company to participate in both treatment delivery and emerging therapeutic development markets.

Business Operations

Braxia Scientific has historically operated through clinic-based psychiatric care and research-oriented business units. Its operations have included specialized treatment centers offering ketamine-assisted therapies for treatment-resistant depression and related psychiatric conditions. The company has also pursued observational studies and clinical research initiatives designed to support the medical use of psychedelic-assisted therapies within regulated healthcare frameworks. Revenue generation has primarily been tied to healthcare services, consultations, treatment programs, and associated clinical activities.

The company’s operations have been concentrated largely in Canada, though its strategic outlook has reflected broader international interest in psychedelic medicine and mental health therapeutics. Braxia has controlled clinical assets through affiliated treatment facilities and research programs connected to psychiatric care delivery. Public disclosures have also referenced collaborations with medical professionals, researchers, and healthcare practitioners involved in neuropsychiatric treatment development. Data regarding certain partnerships and operational scale has been limited or evolving in recent public disclosures, and some information is inconclusive based on available public sources.

Strategic Position & Investments

Braxia Scientific’s strategic direction has centered on expanding evidence-based mental health treatment options while participating in the emerging psychedelic therapeutics market. The company has emphasized research into ketamine and related compounds for depression and PTSD treatment, positioning itself within a broader healthcare trend toward alternative psychiatric therapies. Its strategy has combined healthcare delivery infrastructure with clinical data collection and treatment innovation.

The company has previously pursued acquisitions and investments connected to psychiatric clinics and mental health treatment operations to strengthen its clinical footprint. Public filings and corporate disclosures have indicated a focus on integrating research capabilities with patient treatment services, though the scale and pace of expansion have varied over time due to market conditions and capital availability. Braxia has also been associated with the development of intellectual property and treatment protocols related to psychedelic-assisted mental healthcare. Information regarding newer investments or active portfolio expansion remains limited in publicly available filings.

Geographic Footprint

Braxia Scientific is headquartered in Canada, with operations historically concentrated in Ontario and other Canadian healthcare markets. The company’s clinical and research activities have primarily served Canadian patients seeking treatment for depression, PTSD, and related psychiatric conditions. Its operational footprint has been more limited compared with larger multinational biotechnology or pharmaceutical companies, though its business strategy has aligned with broader international developments in psychedelic medicine.

The company has participated in a sector that attracts significant interest across North America and internationally, particularly in jurisdictions exploring regulated psychedelic-assisted therapies. While Braxia’s direct operational presence outside Canada has not been extensively documented in public filings, its research focus and industry positioning place it within a globally emerging mental health therapeutics market. Data regarding material international subsidiaries or large-scale overseas operations is inconclusive based on available public sources.

Leadership & Governance

Braxia Scientific has been led by executives with backgrounds in healthcare, psychiatry, biotechnology, and capital markets. Leadership strategy has generally emphasized expanding access to mental health treatment while supporting clinically validated psychedelic and ketamine-assisted therapies. The company’s governance structure has reflected the regulatory and research-oriented nature of the healthcare sector in which it operates.

Key executives and leadership figures identified in public disclosures have included:

• Dr. Roger McIntyre – Founder and former executive leader associated with the company’s clinical and scientific direction
• Shawn Moniz – Chief Executive Officer
• Dr. Roger McIntyre – Scientific and psychiatric leadership roles tied to research strategy
• Board of Directors and healthcare advisors – Oversight of corporate governance, clinical standards, and strategic development

Certain executive roles and board compositions have changed over time, and some current leadership details may vary across public filings and market disclosures.